Finnegan client Eli Lilly & Co. filed an infringement suit May 5 in the District of New Jersey against Zydus Pharmaceuticals “accusing it of breaching a consent order entered in a previous case Lilly brought over attention deficit hyperactivity disorder treatment Strattera®.” Lilly contends that Zydus willfully did not amend its ANDA to convert its patent certification from one under Paragraph IV to one under Paragraph III following the consent order's entry. Lilly is represented by Finnegan in this matter.
Award/Ranking
Finnegan Named Firm of the Year at the 2024 Managing Intellectual Property Americas Awards
April 26, 2024
Commentary
Behind the Case: How Finnegan Helped Eli Lilly Swerve a $176.5M Patent Headache
October 10, 2023
Award/Ranking
Finnegan Recognized as Leader in Intellectual Property Litigation at 2013 LMG Life Sciences Awards
September 26, 2013
Award/Ranking
September 18, 2012
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.